Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 16/20 | 0.49 |
| ▸ | F2 | P00734 | 7/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
| ▸ | F3 | P13726 | 6/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847414 | 0.94 | F7 (0.51) | F7F2F10F3PRSS1 | |
| Hydrochloric Acid SCHEMBL5846292 | 0.93 | F7 (0.51) | F7F2F10F3PRSS1 | |
| SCHEMBL5847197 | 0.83 | CYP1A2 (0.48) | F7F2F3PRSS1CYP1A2 | |
| SCHEMBL14537324 | 0.81 | F2 (0.50) | F7F2F3CYP1A2CYP2C9 | |
| SCHEMBL5847925 | 0.80 | F2 (0.49) | F7F2F10F3CYP1A2 | |
| SCHEMBL5846166 | 0.79 | F2 (0.50) | F7F2F3CYP1A2CYP2C9 | |
| SCHEMBL5846183 | 0.78 | F2 (0.51) | F7F2F3 | |
| SCHEMBL30765979 | 0.73 | F2 (0.45) | F7F2F3CYP1A2CYP2C9 | |
| SCHEMBL23460740 | 0.72 | F7 (0.58) | F7F2F3PRSS1 | |
| SCHEMBL3240576 | 0.72 | MEN1 (0.44) | CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | F7 75/4885F2 6/4885F10 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.